Multidrug resistance (MDR) has been thought to be one of the major obstacles for successful chemotherapy in patients with cancers. The MDR has been associated with overexpression of P-glycoprotein (P-gp) in cancer cells.
It has been demonstrated that some P-gp inhibitors could effectively reverse P-gp mediated MDR in in vitro experiments. Among the P-gp inhibitors identified, verapamil (VER) was the first which has potent effect on reversal of MDR through inhibition of P-gp. 5) Subsequently, a number of other structurally unrelated compounds such as cyclosporin, phenothiazines, antimalarials and antibiotics have also been demonstrated to be effective P-gp inhibitors of Pgp. 6, 7) However many of these compounds are fail to be introduced to clinical trails due to the unacceptable toxicities for anticancer treatment or nonspecific and weak inhibitory effect on P-gp. Therefore, the development of newer P-gp inhibitors with higher selectivity and stronger potency remains a major goal for this field of research.
Calmodulin is a calcium-binding protein that may play a role in the signaling of insulin-and contraction-stimulated glucose transport. 8) Calmodulin inhibitors may therefore inhibit both contraction/hypoxia-and insulin-stimulated glucose transport. Several calmodulin inhibitors have been found to reverse MDR by inhibiting the P-gp mediated drug efflux. [9] [10] [11] [12] [13] [14] [15] [16] [17] E6, a derivative of berbamine which belongs to bi-bezylisoquinolines, was synthesized by China Pharmaceutical University and exhibited potent calmodulin antagonistic activity (Fig. 1) . 18) Our previous study showed that E6 exhibited strong inhibitory effect on the activity of P-gp in rat brain microvessel endothelial cells (RBMECs). 19) However, the possible reversal effect of E6 on MDR cancer cells has not been investigated. In the present study, we studied the effect of E6 on MDR of K562/DOX cell line that has overexpression of P-gp. 20) In addition, these effects were compared with those in K562 parent cell line. Furthermore, the effect of E6 on the doxorubicin-induced apoptosis were studied and compared in both K562/DOX and K562 parent cells.
MATERIALS AND METHODS
Chemicals E6 was kindly provided by Dr. Wen-Long Hwang (China Pharmaceutical University). 3-(4,5-Dimethylthiazol)-2,5-diphenyltetrazolium bromide (MTT), doxorubicin and VER were purchased from Sigma-Aldrich (St. Louis, MO, U.S.A.). FITC-annexin V and propidium iodide (PI) were obtained from Becton Dickinson (Franklin Lakes, NJ, U.S.A.). All other drugs and reagents were of analytical grade and commercially available.
Cell Lines The drug-sensitive human leukemia cell line, K562, and its drug-resistant variant, K562/DOX, were obtained from Institute of Hematology of Chinese Academy of Medical Sciences (Tianjin, China). The cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C in a humidified atmosphere of 5% CO 2 in air. The K562/DOX cells were grown in the presence of 1 mM doxorubicin, which was withdrawn for two generations before the experiments.
Cytotoxicity Assay Cytotoxicity was assessed by the MTT assay. 21) Briefly, cells were seeded into 96-well culture plates at a density of 5ϫ10 4 cells/ml. Doxorubicin were added alone or with E6 or VER in a final volume of 200 ml per well. After the drugs treatment for 44 h, the medium was replaced with an equal volume of fresh medium containing 0.5 mg/ml MTT and incubated for 4 h at 37°C. After that, the medium was removed and 100 ml DMSO were added and incubated for 30 min at room temperature. The cytotoxic effects of drugs were determined according to the OD values using a microplate reader (Victor 2 1420, Perkin Elmer Life Sciences, Turku, Finland) at absorption wavelength of 570 nm. The concentrations required to inhibit growth by 50% (IC 50 values) were calculated from the cytotoxicity curves using a Bliss's software. The fold-reversal of MDR was calculated by dividing the IC 50 values in the absence of the P-gp inhibitors by those in the presence of the P-gp inhibitors.
Flow Cytometric Apoptosis Assay and Cell Cycle Analysis The DNA content analysis and annexin-V binding assay were used to determine the reversal effect of E6 on the resistance to apoptosis in K562/DOX cells.
Apoptotic cells show diminished DNA content below the G 0 /G 1 population of normal diploid cells. In order to count the cells in sub-diploid and analyze the cell cycle, flow cytometry was used by the method of cell staining with PI. 22) Briefly, after treatment with doxorubicin alone or combined with E6, the cells were centrifuged at 1000 rpm for 5 min, washed twice with Hank's solution; then chilled with cool 70% ethanol and the samples were kept at 4°C for 1 h. Thereafter, internucleosomally fragmented DNA was removed from apoptotic cells by incubation in 0.2 M citrtephosphate buffer (pH 7.8) containing 0.2 mg/ml RNase for 30 min at 37°C. Finally, samples were stained with 25 mg/ml PI at room temperature in the dark. The fluorescence of the remaining DNA content was analyzed in the FL2H, FL2A channels using a flow cytometry (Becton Dickinson, U.S.A.). Data were analyzed with CellQuest software (Becton Dickinson). Apoptosis rate was determined by evaluating the percentage of events accumulated in the pre-G 0 /G 1 position. Cell cycle analysis was done by Modfit LT version 3.0 software (Becton Dickinson).
The second apoptotic method depends on annexin-V binding assay. 23) Briefly, cells were collected by centrifugation, washed twice in PBS, and resuspended in binding buffer at a density of 10 6 cells/ml, then stained with FITC-annexin V and PI for 15 min at room temperature in the dark. The samples were then analyzed by a flow cytometry using CellQuest software (Becton Dickinson). The proportion of apoptotic cells was estimated by percentage of cells that stained positive for annexin V while remaining impermeable to PI (annexin Vϩ and PIϪ); necrosis was determined as positive stain with both annexin V and PI (annexin Vϩ and PIϩ); and viability was defined as annexin VϪ and PIϪ.
Doxorubicin Accumulation and Efflux Assay Doxorubicin accumulation and efflux were analyzed by flow cytometry. 24, 25) In doxorubicin accumulation studies, K562 or K562/DOX cells were incubated at 37°C with 5 mM doxorubicin in the absence or presence of 1, 3, 10 mM E6 or 10 mM VER for 60 min. After incubation, the cells were washed twice with ice-cold PBS, resuspended in 200 ml PBS and then analyzed by flow cytometry.
In doxorubicin efflux studies, cells (1ϫ10 6 ) were incubated with 10 mM doxorubicin at 37°C for 30 min (substrateloading phase) and then washed twice with ice-cold PBS. Thereafter, cells were resuspended in doxorubicin-free RPMI 1640 in the absence or presence of 10 mM E6 or 10 mM VER at 37°C for 0, 5, 15, 30, 60 min. At the defined intervals, cells were harvested, centrifuged and washed in ice-cold PBS. Cell pellets were then resuspended in 200 ml PBS and used immediately for flow cytometic analysis for intracellular doxorubicin retention.
Statistical Methods All results were represented as meanϮS.D. Statistical analysis was performed using Student t-test. Table 1 , K562/DOX cells were resistant to doxorubicin compared with K562 cells. The ability of E6 to reverse the drug resistance of K562/DOX was examined and compared with that of VER. 30 mM of either E6 or VER had no cytotoxic effects on K562/DOX and K562 cells. After K562/DOX cells (Table 1) . E6 was about 4-fold potent than VER in reversing the resistance to doxorubicin in K562/DOX cells. In contrast, E6 and VER, at the concentrations tested, had no effect on doxorubicin cytotoxicity in K562 cells (Table 1) .
RESULTS

Effect of E6 on Doxorubicin Cytotoxicity As shown in
Apoptosis Induced by Combining Doxorubicin and E6
The appearance of sub-diploid DNA peak is a specific marker of apoptosis; necrosis induced by metabolic poisons or lysis produced by complement did not induce any subdiploid peak in the DNA fluorescence histogram. Results of DNA content analysis showed that the sub-diploid DNA peak percentage induced by doxorubicin in K562/DOX was greatly enhanced in the presence of E6. After the cells were treated with 3 mM doxorubicin combined with 1, 3 and 10 mM E6 for 24 h, the sub-diploid DNA peak percentages of K562/DOX cells were approximately 2-, 5-and 7-fold higher, respectively, than that treated with doxorubicin alone. The percentage of cells arrested in the G 2 /M cell cycle phase showed good agreement with the trends of the apoptosis induced by the drugs (Table 2 ). In sensitive K562 cells, E6 or VER has no significant effects on the apoptosis and G 2 /M cell cycle phase arrest induced by doxorubicin (data not shown).
Annexin-V is a Ca 2ϩ dependent phospholipid-binding protein with high affinity for phosphatidylserine (PS). When cell death occurs, PS is translocated from the inner side of the plasma membrane to the out layer, by which PS becomes exposed at the external surface of the cell. This occurs in the early phase of apoptotic cell death during which the cell membrane itself remains intact. Therefore, the measurement of annexin-V binding, executed simultaneously with a dye exclusion test (PI staining), provided a useful assay to detect apoptotic cells and to discriminate between apoptosis and necrosis.
According to the annexin-V binding assay, E6 and VER obviously enhanced doxorubicin-induced apoptosis. After treatment of 10 mM VER or 10 mM E6 for 24 h, the apoptotic percentages of K562/DOX induced by 3 mM doxorubicin were increased from 6.97% to 15.15 or 25.77%, respectively (Fig. 2) .
E6 or VER has no significant effect on apoptosis induction or alteration of cell cycle in K562/DOX cells in the absence of doxorubicin (Table 3) . 
Effect of E6 on Intracellular Accumulation and Efflux of Doxorubicin
The effect of E6 on the intracellular accumulation of doxorubicin was examined using flow cytometry. The accumulation levels of doxorubicin in K562/DOX cells were examined after the cells were incubated with 5 mM doxorubicin at 37°C for 60 min in the absence or presence of E6 (1-10 mM) or VER (10 mM). Co-administration of E6 or VER markedly enhanced the doxorubicin accumulation in K562/DOX cells, and E6 had stronger effects that of VER at the same concentration (Fig. 3) . However, E6 or VER had no such effect in K562 sensitive cells (data not shown).
The efflux of doxorubicin from K562/DOX and K562 cells was detected by flow cytometry. After incubation with 10 mM doxorubicin at 37°C for 30 min, the cells were resuspended in doxorubicin-free medium in the absence or presence of 10 mM E6 or VER at 37°C for the indicated times. The levels of doxorubicin in K562/DOX cells were lower than that in K562 cells at 15, 30, 60 min. E6 as well as VER obviously inhibited the efflux of doxorubicin from K562/DOX cells, but not from K562 cells. At 10 mM, E6 was more effective than VER (Fig. 4) . The results from both accumulation and efflux experiments indicated that E6 could effectively increased the intracellular concentration of doxorubicin in K562/DOX cells.
DISCUSSION
Previous studies have demonstrated that structurally unrelated calmodulin inhibitors, such as berbamine, phenothiazine, trifluorapine, trifluoperazine and nifedepine, exhibited various extent of inhibitory effects on P-gp-mediated drug efflux and reversed MDR in various cancer cells. [9] [10] [11] [12] [13] [14] [15] [16] [17] 26) Recently, we demonstrated that E6, a strong calmodulin inhibitor derived from berbamine, 17, 18) exhibited potent inhibitory effect on activity of P-gp in primary cultured RBMECs. 19) In the present study, it was further demonstrated that E6 strongly reversed MDR in a K562 subline, K562/ DOX. In addition, we provided direct evidence that E6 enhances the doxorubicin-induced apoptosis by markedly decreasing the intracellular doxorubicin concentration in K562/ DOX cells.
While understanding the structural and functional relationships of P-gp and its substrates and inhibitors remains a major challenge for pharmacological and pharmaceutical research, many newer MDR reverters have been developed and their in vitro effects have been verified. 27) However, few of these MDR reverters achieve clinical success. Actually, there are currently no reversal agents clinically available. A major reason for this lack of clinical success is owing to the deleterious effect of the reversal agents on normal tissues expressing P-gp and their intrinsic toxicities in vivo. 27) This has been the major problem encountering for the second and third generations of MDR reversal agents. Therefore, development of potent yet selective P-gp inhibitors remains to be a major task for this field of research. [28] [29] [30] In the present study, E6 was verified to have greater potency than that of positive-control VER in reversing the MDR in a drug resistance cancer cell line, K562/DOX. According to our preliminary data, E6 also has feasible in vivo features which allow it to be safely administered in high doses without apparent toxicities. These may favor E6 to be further tested as a reversal agent in clinical trails. However, considering E6 exhibits potent calmodulin inhibitory activity, the possible side effects caused by calmodulin inhibition must be taken into account in the further MDR reversal studies of E6.
A number of mechanisms have been implicated in the development of MDR by cancer cells, including over-expression of P-gp, 31) multidrug resistance related protein (MRP), 32) lung resistance protein (LRP), 33) and breast cancer resistance protein (BCRP). 34) Recently, it has been reported that a post-transcriptional upregulation of P-gp is responsible for the MDR in K562/DOX, and MRP and LRP may play only minor role. 35) Therefore, reversal of the over-expressed P-gp function in K562/DOX is the most likely explanation for the observed E6 effect in the K562/DOX cell line. This is further evidenced by our previous results in RBMEC, in which the cellular transport of a typical P-gp substrate, rhodamine 123, was markedly inhibited by E6, indicating a P-gp inhibitory effect of E6. 19) However, we acknowledge that the present study can not provide any firm evidence into the extract molecular mechanisms involved in the MDR reversal effect of E6. Considering that multiple mechanisms are involved in the MDR of cancer chemotherapy, comparing the MDR reversal effects of E6 in different cancer cell lines overexpressing different levels of MDR transporters may deserve further investigation.
In conclusion, the present study provides evidence that E6 effectively reversed MDR in a K562/DOX cell line. The doxorubicin-induced apoptosis was enhanced and the intracellular concentrations of doxorubicin were greatly increased by the treatment of the cells with E6. The strong MDR reversal effects of E6 as well as its favorable in vivo features make it a possible choice for further mechanistic and pharmacokinetic experiments.
